Drug & Cancer & Variant
Result
Search content: Drug = AKTi-1/2
There are 1 entries with your keyword(s).
Gene Variant Type Tumor Drug Drug level Reference More
ERBB2 AMP CNA Breast Cancer AKTi-1/2 V 1
Evidence region

CIVIC

Patient Criteria

-

Note

Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (AKTi-1/2; naphthyridinone).

Gene name

ERBB2

Full name

erb-b2 receptor tyrosine kinase 2

Gene type

protein-coding

Function

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]

Sorry, there is no related drug information.

Showing 1 to 1 of 1 entries, entries per page